MYND Life Sciences Inc
CNSX:MYND
MYND Life Sciences Inc
MYND Life Sciences, Inc. is a neuro-pharmaceutical drug development company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2021-05-26. The firm is focused on conducting research linking depression and inflammation at the genetic and cellular level to develop a pharmaceutical treatment utilizing compounds found in psychedelics with the initial focus being on psilocybin and its various analogs. The company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder (MDD). The Company’s lead development program, referred to as the Human Mycogene Modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin. The company is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions.
MYND Life Sciences, Inc. is a neuro-pharmaceutical drug development company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2021-05-26. The firm is focused on conducting research linking depression and inflammation at the genetic and cellular level to develop a pharmaceutical treatment utilizing compounds found in psychedelics with the initial focus being on psilocybin and its various analogs. The company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder (MDD). The Company’s lead development program, referred to as the Human Mycogene Modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin. The company is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions.
